Tirabrutinib

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Pharmacology

5 evidence topics · 5 sources